Company intelligence / Profile preview

Tympanogen

Richmond, Virginia, United States

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Perf-Fix Otologic Gel Patch, the lead product, is a nonsurgical gel patch for eardrum repair based on a proprietary hydrogel system. It aims to allow outpatient repair of tympanic membrane perforations efficiently and safely. The product is in pre-commercial/late development, not yet commercially available, with company fundraising ongoing for anticipated rollout in 2026. Preclinical and early clinical results indicate rapid healing rates and high-quality tissue regeneration comparable to traditional surgical tympanoplasty but with lower burden for patients and providers.

Therapeutic areas: OtherInfectious Diseases
Modalities: DeviceHydrogel-based drug delivery therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Tympanogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tympanogen.

Explore the full profile